Adam R. Craig

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Jörge E. Cortes, Jeff H. Lipton, Delphine Réa et al. · Blood · 2012 · 135 citations · Full text

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Aaron T. Gerds, Michael R. Savona, Bart L. Scott et al. · Blood Advances · 2020 · 83 citations · Full text

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

Elaine Allan, Tessa L. Holyoake, Adam R. Craig et al. · Leukemia · 2011 · 80 citations

Hematological Malignancy, Stem/progenitor Cells, Malignant Blood Disorder +8

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

Jörge E. Cortes, Raghunadharao Digumarti, Purvish M. Parikh et al. · American Journal of Hematology · 2013 · 64 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Pharmacotherapy +27

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Stephen T. Oh, Ruben A. Mesa, Claire Harrison et al. · Blood Advances · 2023 · 60 citations · Full text

Antifibrotic Therapy, Immunology, Cardiovascular Pharmacology +17